Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
WESTFORD, Mass., May 17, 2011 /PRNewswire/ -- Cynosure, Inc. (Nasdaq: CYNO ), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced the receipt of two additional international clearances for the Company's new flagship workstations for cellulite reduction.
Cynosure has received regulatory clearance from Australia's Therapeutic Goods Administration (TGA) for its Cellulaze™ Cellulite Laser Workstation, the world's first minimally invasive surgical device for the long-term reduction of cellulite. The Company also has obtained approval to market its SmoothShapes XV, a non-invasive system for the temporary reduction in the appearance of cellulite, from the Taiwan Food and Drug Administration (TFDA). Cynosure plans to sell these products through its independent distributors in each country.
"Australia and the Asia Pacific are important and attractive markets for Cynosure as we focus on expanding the international reach of our newest products, particularly our cellulite platform," said President and Chief Executive Officer Michael Davin. "Consumer demand for aesthetic procedures in these countries is strong, and practitioners are eager to integrate new technologies capable of providing safe, efficacious treatments that result in high levels of patient satisfaction. We are encouraged about the prospects for Cellulaze and SmoothShapes XV as we grow their distribution channels and build global product recognition."
Cellulaze and SmoothShapes XV have received CE Mark certification in the European Union. SmoothShapes XV also is cleared for marketing in the United States.
Cellulaze, which uses laser thermal energy to target cellulite beneath the surface of the skin, is designed to restore the skin's normal structure and underlying connective tissue. A recently prese